The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study

다국어 초록 (Multilingual Abstract)

Objective: Our aim was to determine if the time interval between bowel resection and initiation of adjuvant chemotherapy impacts survival in advanced ovarian cancers. Methods: This was a retrospective cohort study using data from two cancer centers, Princess Margaret Cancer Centre in Toronto, Ontario, Canada and Samsung Comprehensive Cancer Center in Seoul, South Korea. Patients with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer that underwent large bowel resection during primary cytoreductive surgery (PCS) were included.
Results: Ninety-one women were eligible of which the majority (90.1%) were diagnosed with high-grade serous cancer. The median interval from PCS to chemotherapy for all patients was 21 days (7–86 days). Patients were stratified into 3 groups: 1) Interval ≤14 days, 32 (35.2%) patients; 2) Interval between 15–28 days, 27 (29.6%) patients; and 3) Interval between29–90 days, 32 (35.2%) patients. Surgical procedures and postoperative outcomes were similar between groups. Multivariate analysis indicated that PCS to chemotherapy interval of 2–4 weeks, younger age, and completion of 4 or more adjuvant chemotherapy cycles were independent prognostic factors of favorable overall survival.
Conclusion: Initiation of adjuvant chemotherapy between 2 to 4 weeks after PCS with bowel resection may improve survival outcomes in women with advanced ovarian cancer by maximizing the benefit of PCS plus adjuvant chemotherapy.

참고문헌 (Reference)

1 Lee Y, "Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model" 11 : 56-, 2018

2 Maniwa Y, "Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer" 114 : 1668-1675, 1998

3 Bos AC, "Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer" 51 : 2553-2561, 2015

4 Djedovic V, "The two faces of adjuvant glucocorticoid treatment in ovarian cancer" 9 : 95-107, 2018

5 Bogani G, "The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer : results from a multi-institutional study" 27 : 1856-1862, 2017

6 Lee JW, "The effect of surgical wound on ovarian carcinoma growth in an animal model" 33 : 3177-3184, 2013

7 Chan JK, "The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients-an analysis of NRG Oncology/Gynecologic Oncology Group trials" 143 : 490-495, 2016

8 Curigliano G, "Systemic effects of surgery : quantitative analysis of circulating basic fibroblast growth factor(bFGF), vascular endothelial growth factor(VEGF)and transforming growth factor beta(TGF-beta)in patients with breast cancer who underwent limited or extended surgery" 93 : 35-40, 2005

9 Tagliabue E, "Role of HER2 in woundinduced breast carcinoma proliferation" 362 : 527-533, 2003

10 Liu Y, "Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients : a dose-response meta-analysis of cohort studies" 7 : 9461-, 2017

11 Fisher B, "Presence of a growth-stimulating factor in serum following primary tumor removal in mice" 49 : 1996-2001, 1989

12 Elattar A, "Optimal primary surgical treatment for advanced epithelial ovarian cancer" 2016 : CD007565-, 2011

13 Coleman RL, "Latest research and treatment of advanced-stage epithelial ovarian cancer" 10 : 211-224, 2013

14 Lacy AM, "Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer : a randomised trial" 359 : 2224-2229, 2002

15 Fisher B, "Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases" 43 : 1488-1492, 1983

16 Virrey JJ, "Increased survivin expression confers chemoresistance to tumor-associated endothelial cells" 173 : 575-585, 2008

17 Amin AT, "Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model" 24 : 1427-1433, 2010

18 Wang BY, "Impact on survival on interval between surgery and adjuvant chemotherapy in completely resected stage IB-IIIA lung cancer" 11 : e0163809-, 2016

19 Lohrisch C, "Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer" 24 : 4888-4894, 2006

20 Arora M, "Impact of radical bowel resection on survival in advanced epithelial ovarian cancer" 23 : 5166-, 2005

21 Lee YY, "Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer" 143 : 325-332, 2018

22 May T, "Examining survival outcomes of 852 women with advanced ovarian cancer : a multi-institutional cohort study" 28 : 925-931, 2018

23 Larsen E, "Epithelial ovarian cancer : does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?" 88 : 373-377, 2009

24 Simpson-Herren L, "Effects of surgery on the cell kinetics of residual tumor" 60 : 1749-1760, 1976

25 Kolb BA, "Effects of early postoperative chemotherapy on wound healing" 79 : 988-992, 1992

26 Zhang B, "Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer" 28 : 619-625, 2006

27 Tewari KS, "Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival : NRG Oncology/Gynecologic Oncology Group study" 27 : 114-121, 2016

28 Usón PL, "Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data" 27 : 274-280, 2017

29 Eisenkop SM, "Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer : a prospective study" 69 : 103-108, 1998

30 Biagi JJ, "Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer : a systematic review and meta-analysis" 305 : 2335-2342, 2011

31 Yu KD, "Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer : a systematic review and meta-analysis" 13 : 240-, 2013

32 Lange PH, "Acclerated growth of testicular cancer after cytoreductive surgery" 45 : 1498-1506, 1980